

Effects of T-type calcium channel blockers on a parkinsonian tremor model in rats

Hideto Miwa^{*}, Jinsoo Koh, Yoshinori Kajimoto, Tomoyoshi Kondo

Department of Neurology, Wakayama Medical University, 811-1 Kimiidera, Wakayama 641-8510, Japan

ARTICLE INFO

Article history:

Received 16 September 2010

Received in revised form 15 November 2010

Accepted 18 November 2010

Available online 26 November 2010

Keywords:

Tremor

Parkinson's disease

T-type calcium channel

Zonisamide

Ethosuximide

ABSTRACT

T-type calcium channels are strongly associated with the generation of rhythmic firing patterns in the CNS. Blockers of these channels may have therapeutic potential for treating various types of tremor. The present study aimed to study the effects of a range of T-type calcium channel blockers in a parkinsonian tremor model in rats. We tested the effects of several T-type calcium channel blockers, including zonisamide (ZNS), ethosuximide, lomerizine, amiloride, mibefradil, and NCC 55-0396, a mibefradil derivative, on tacrine-induced tremulous jaw movements (TJMs), an animal model of parkinsonian tremor. Among the tested drugs, only ZNS and NCC 55-0396 significantly suppressed TJMs when given at a non-sedating dose. The transitivity of drugs to the central nervous system (CNS) may at least partially explain their differential anti-TJM effects. However, further studies are necessary to reveal other factors, since ethosuximide failed to show anti-TJM effects despite being known to cross the blood brain barrier. The present results suggest that T-type calcium channels in the CNS may be a suitable target for developing new therapeutic strategies for treating parkinsonian tremor.

© 2010 Elsevier Inc. All rights reserved.

1. Introduction

Voltage-gated calcium channels (VGCCs) mediate the entry of calcium ions into cells, and are involved in a variety of calcium-dependent processes such as muscle contraction, neurotransmitter release, gene expression, and cell division or death (Lory and Chemin, 2007). VGCCs are divided into two major functional classes: high-voltage-activated and low-voltage-activated channels (Catterall, 2000). Among these, 'T-type calcium channels' refer to transient or low-voltage-activated channels. T-type calcium channels are reported to be strongly associated with the generation of rhythmic firing patterns in the CNS (Llinás and Yarom, 1981; Gutnick and Yarom, 1989), raising the possibility that blockers of these channels may have therapeutic potential for tremors. It was recently reported that T-type calcium channel blockers exhibited anti-tremor effects on harmaline-induced tremor, an experimental model of essential tremor (Yang et al., 2008; Handforth et al., 2010). The olivocerebellar system has been shown to play a key role in the tremor-generating mechanisms underlying harmaline-induced tremor (Llinás and Yarom, 1981; Wilms et al., 1999; Cavalier et al., 2008; Miwa et al., 2008). In addition, experimental studies have revealed that Purkinje cell complex spikes are mediated by T-type calcium channels (Cavalier et al., 2008), and that $\text{Ca}_v3.1$ T-type calcium channels in the inferior olive nucleus are involved in the tremor-rhythm pacemaker in harmaline-induced tremor (Park et al., 2010). These findings suggest that T-type calcium channel blockers may directly

inhibit tremor-rhythm generation in the olivocerebellar system, resulting in an improvement of tremors. In accord with this notion, recent clinical studies demonstrated that zonisamide (ZNS), a widely used antiepileptic drug with a T-type calcium channel blocking action, successfully ameliorated essential tremor (Morita et al., 2005; Song et al., 2008; Handforth et al., 2009). Since it could be speculated that tremor-generating rhythmic firing is present in not only the olivocerebellar system but also other functional systems in the CNS such as the basal ganglia, T-type calcium channel blockers may have therapeutic potential for treating parkinsonian tremor, for which tremor-generators exist in the basal ganglia.

Thus, it is important to determine whether or not currently available T-type calcium channel blockers suppress experimental parkinsonian tremors. Unfortunately, there has been limited research into the anti-tremor effects of T-type calcium channel blockers, in terms of both experimental tremors in animals and human tremor disorders. The primary purpose of the present study was to investigate the effects of several currently available T-type calcium channel blockers, including ethosuximide, ZNS, lomerizine, amiloride, mibefradil, and the mibefradil derivative NCC 55-0396 (Huang et al., 2004), on tacrine-induced tremulous jaw movements (TJMs) in rats (Salamone et al., 1998; Salamone et al., 2005). Most of these drugs are already used in clinical settings. Tacrine-induced TJMs are considered a rat model of parkinsonian tremor (Miwa, 2007b; Salamone et al., 1998; Salamone et al., 2005). Clinically, the development of new therapeutics that specifically treat parkinsonian tremor is important, because it is one of the most important factors associated with the quality of life impairment in patients with Parkinson's disease (PD), and is often residual even after dopamine

^{*} Corresponding author. Tel./fax: +81 73 441 0655.

E-mail addresses: h-miwa@wakayama-med.ac.jp, hmiwahmiwa@gmail.com (H. Miwa).

replacement therapy has been initiated. Unfortunately, no previous studies have examined the effects of T-type calcium channel blockers other than ZNS using the parkinsonian tremor model (Miwa et al., 2008). The present study sought to provide information helpful for the development of new therapeutic strategies for the treatment of parkinsonian tremor.

2. Methods

2.1. Subjects

The subjects were adult male Sprague–Dawley rats (N=36), weighing 250–380 g at the time of the experiments. The animals were housed in cages and kept in a temperature-controlled room under a 12 h/12 h light/dark cycle. Food and tap water were freely accessible. The experimental protocols were approved by Wakayama Medical University's Animal Care and Use Committee.

2.2. Drugs

Ethosuximide, amiloride HCl, lomerizine HCl, and mibefradil are all known to have T-type calcium channel blocking actions, and have all been used widely in clinical settings. NCC 55-0396, a derivative of mibefradil, is a potent and T-type calcium channel blocker that is more selective than mibefradil (Huang et al., 2004). These drugs were purchased from Sigma-Aldrich (USA). Zonisamide HCl was generously provided by Dainippon-Sumitomo Pharmaceuticals (Japan). All drugs were prepared immediately prior to administration.

2.3. Procedures

Cholinomimetic-induced TJMs have been proposed as a pharmacological model of Parkinsonian tremor in rodents (Salamone et al., 1998; Salamone et al., 2005). To examine the effects of T-type calcium channel blockers on tacrine-induced TJMs, a T-type calcium channel blocker or the same amount of a control vehicle, was administered intraperitoneally. Subsequently, 30 min later, 9-amino-1,2,3-tetrahydroaminoacridine HCl (tacrine; Sigma-Aldrich, St Louis, MO, USA; 5 mg/kg, dissolved in saline) was administered intraperitoneally. Ten minutes after the administration of tacrine, tacrine-induced TJMs were measured for 5 min by two experienced observers (J.K. and Y.K.) who were unaware of the treatment procedures. TJMs were defined as vertical deflections of the lower jaw that resemble chewing, in accord with previous reports (Salamone et al., 1998; Salamone et al., 2005). In addition, sedation was semi-quantified with a sedation score determined by the response to external stimulation including sound, and whisker touching (0 = awake and active; 1 = awake, but composed, with preserved response to external stimulation; 2 = sedated, with preserved response only to intense external stimulation, and slow response; and 3 = overly sedated and unresponsive to external stimulation). Inter-rater variability was found to be significant by linear regression analysis ($r=0.88$, $P<0.05$). The median sedation scores obtained were analyzed statistically. Rats were tested for a period of at least one week. Consistent with earlier studies, vehicle levels of TJM activities were consistent across the repeated weeks of the study. Over the course of the study, pharmacobehavioral studies were performed either two or three times in each rat.

2.4. Data analysis

TJMs and sedation scores were represented as mean $\pm$ SE and median, respectively. Differences between groups were examined with a non-parametric Kruskal–Wallis test, and a Mann–Whitney test was used for comparisons between the two groups. The level of statistical significance was set at $P<0.05$.

3. Results

Tacrine-induced TJMs that were measured following the administration of each drug and vehicle in each experiment were demonstrated (Fig. 1). As shown in Fig. 1, ZNS significantly suppressed tacrine-induced TJMs in a dose-dependent manner (Fig. 1A).




Fig. 1. Anti-tremor effects of T-type calcium blockers on tacrine-induced tremulous jaw movements (TJMs) per 5 min. Data are shown as mean (columns) and S.E. (bars). The results of experiments performed with each drug treatment. Either four or five rats were tested with each drug dose. Sedation scores were simultaneously obtained. Asterisks in the TJM data indicate * $P<0.05$ (* vs. control; ** vs. 5 mg/kg). Asterisks in data of sedation score indicate * $P<0.05$ and ** $P<0.01$ vs. control.

Download English Version:

<https://daneshyari.com/en/article/2013413>

Download Persian Version:

<https://daneshyari.com/article/2013413>

[Daneshyari.com](https://daneshyari.com)